reason report
outlook shift valu gener brand price
bottom line coverag primarili driven three
macro trend on-going gradual shift value-bas care
continu headwind brand gener price trend pharma
suppli chain earli impact mco/pbm/retail integr
hcit coverag continu prefer stock well
posit continu albeit gradual shift valu based-car
includ evol health op op remain
cautiou distributor much pharma suppli chain
continu aggress action fda like weigh gener
drug price deflat brand price inflat larg conting
januari price hike may risk given high level scrutini
washington vertic integr ci-esrx cvs-aet
becom realiti view like drive competit
volum margin compress retail pharmaci dental
anim health market current robust grow like
remain healthi bode well op top
pick op op op featur
strong end-market healthi demand attract growth profil
support macro tailwind
gradual march toward value-bas care still continu
hcit continu rhetor action administr seema
verma hh secretari azar support value-bas care
continu favor hcit compani posit help hospit
health system make shift valu august propos
rule pathway success seek faster assumpt dual-sid risk
account organ aco medicar share save
program mssp believ rule along hh
action continu drive demand value-bas care servic
popul health manag tool hospit main
sourc purchas demand believ value-bas care focus
solut continu garner signific portion hospit capit
budget top pick hcit coverag includ evol health
op remain pure public compani popul health
value-bas care manag servic op
increasingli robust popul health offer veeva system
op bio-pharma market leader posit
capit continu growth life scienc market
pharma suppli chain continu navig macro headwind
remain cautiou pharma suppli chain believ
macro headwind includ brand gener price trend continu
weigh group fda set new record gener
approv tent approv fda aggress
reduc time take agenc bring gener drug market
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
decemb edt rx trend deriv im health
buy-sid gener deflat hover high single-to-low double-
digit rang see littl recours distributor pharma suppli
chain brand price inflat larg conting januari price
hike may risk given heighten scrutini drug price
focu trump administr washington
vertic integr becom realiti like
bring competit retail volum sourc rate
follow recent close cvs-aet deal pend ci-esrx
deal slate close year-end year
integr follow integr may least five larg
mco/pbm/retail vertic integr giant domin market
industri giant align drug purchas consortium
retail channel view like intens competit
market past sever year like continu retail pharmaci
gross margin walgreen declin significantli sinc
compani compet retail volum view
competit like continu acceler given
increas scale industri particip meanwhil amazon lurk
potenti futur threat continu work jpm-brk-amzn
partnership pharma offer follow acquisit pillpack
dental end-market remain healthi continu
thrive remain confid outperform rate remain
well posit capit healthi end-market dental
anim health industri good econom backdrop high level
consum optim bode well continu dental demand sinc
patient get dental insur employ high
employ rate like key driver dental growth longer-
term secular trend support companion anim market also
continu bode well anim health busi like
ownership stake compani retain vet first choic
follow spin-off busi good market posit
support macro trend excel manag team remain
confid go-forward strategi
top pick evol op
op op
hhs/cm push vbc promot acceler risk assumpt pathway success propos rule
migrat care lower cost site continu rise healthcar cost remain unsustain trend
continu hospit health system drive standard system seek scale effect
assum risk manag health popul
drug medic distribut price woe continu januari remain
fda set new record anda approv remain aggress gener deflat continu
brand inflat larg conting price hike januari may risk due increas scrutini
industri consolid may drive increment price pressur cvs/aet ci/esrx gain addit scale
trump administr remain commit lower drug price
pbm retail mco vertic integr becom realiti
ci-esrx merger receiv doj approv plan close cvs-aet close merger
mean vertic integr becom realiti chang pbm-mco landscap view
integr consolid expect retail margin remain pressur competit fierc
amazon remain overhang follow pillpack acquisit on-going jpm-brk-amzn partnership
value-bas trend continu growth life
scienc dental volum dental servic organ
hh appear support shift valu
base care issu propos rule intend
speed assumpt risk
success seek forc faster assumpt
dual-sid risk account organ
aco medicar share save program
 propos rule along propos rule
continu rhetor seema verma hh
azar support shift valu highlight
govern on-going support risk assumpt
lofti goal valu base
leavitt partner present himss confer
 hh maintain lofti goal value-bas care
assumpt sought tie least
medicar spend altern payment model
apm fee-for-servic ff spend
qualiti valu
popul health manag remain top prioriti
 popul health remain top prioriti hospit
capit budget base medacorp survey
 former hh secretari tom price estim
shift valu slow slightli
 vocal support new hh secretari azar
anticip renew focu priorit
popul health invest initi
inform relat revenu cycl access revenu cycl project hospit invest capit order build expand hcit capabl select appli hcit distribut
hospit health system drive major
all-tim high hospit activ drive
 partli anticip larger shift valu base care
market continu shift lower cost site
 hospit health system continu purchas
physician group practic ambulatori care center
even nurs home facil order better manag
health patient popul
 survey shown replac market
slow medacorp kol explain
purchas decis see result
continu hospit health system consolid
 privat held epic op
hcit capit budget alloc declin
common beneficiari standard
less money costli platform
 follow meaning use mu market
satur hospit purchas costli solut
 popul health value-bas care-focus offer
remain top prioriti hospit hcit capit budget
 meanwhil hcit capit budget declin post
mu replac market slow significantli
capit budget percent y/i chang bp hcit budget eaverag y/i chang capit budget follow year percentag expect alloc healthcar inform technolog hcit mm hcit distribut
gener deflat though stabil like continu
gener deflat continu y/i declin
 gener deflat appear stabil consist
manag commentari howev analysi nation
averag drug acquisit nadac price
suggest gener deflat continu y/i
 longer guid gener price trend expect
trend similar end guid sell-sid
pattern similar stabl continu deflat
indic competit stabl gener market
 view high stabl gener deflat rate still
signific headwind group
fda remain aggress promot competit drug
fda approv set new record
 fda set new record anda drug approv
lower median first full approv time day
day
 fda also aggress tent approv ta
often award drug still patent
exclus agenc lower median ta approv time
day day
 fda remain aggress promot competit
like market face continu gener deflat throughout
fda activ yearpre-gdufa supplement submiss backlog approv approv tent supplement respons origin receiv master file complet assess fda hcit distribut
brand price inflat continu declin amid heighten
fda approv set new record
 brand price inflat temper significantli sinc
continu scrutini trump administr
appear price trend continu moder
 distributor profit still tie part list price
mean continu weak brand price inflat
may lead margin compress
 expect mid-singl digit inflat expect
temper mid-singl digit inflat expect mid-
singl inflat consist analysi im data
brand price inflat larg conting januari
 rate inflat brand drug continu slow
suppli chain roil comment fewer
brand drug price increas juli
 analysi im pricerx data show januari
overwhelmingli import month brand drug
 heighten scrutini drug price especi
may put typic januari price hike pattern risk
histor fewer materi price hike
occur januari
brand price hike occur primarili januari
cvs-aet ci-esrx deal chang landscap
year mco-pbm integr
 cvs-aet deal close ci-esrx expect
close year-end landscap
chang vertic integr becom realiti five
 consolid may continu stand-alone player like
may seek bolster posit acquisit
 cvs-aet look chang care deliveri process
front door healthcar strategi
competit retail volum like acceler
challeng environ continu
 expect continu competit retail pharmaci
competit volum driven margin
sell season remain competit mco-pbm
integr lead larger scale may tri lower
rate captiv aet live
 brand gener price trend like present
amazon remain overhang
 though pharma suppli chain hysteria fade
e-commerce giant lurk shadow work continu
jpm-brk-amzn partnership amzn
acquisit pillpack ensur compani remain activ
space
top hcit distribut stock
demand valu base care solut remain robust client
invest client
 ad client year-to-d high end
 describ competit advantag medacorp kol
investor concern buy busi
solut dont sell
new centuri health acquisit offer abil
dilut exist sharehold fund acquisit
live book afford larg in-sel opportun
enhanc margin
fundament remain solid beaten consensu revenu
last quarter ebitda posit
quarter adj ep posit
 convert offer follow acquisit new centuri
fuel concern dilut futur deal
speed shift valu base care
 long await shift valu base care happen
continu slow pace
 net win expans invest
guidanc like march
announc septemb
 rais convert
offer octob
short interest float
veeva well like trust platform life scienc market
continu grow fast pace featur healthi double-digit
margin lead market posit addit solut
plan launch like veev set-up year ahead
boast broad portfolio product commerci
clinic product cover entir life-cycl product
develop commerci
 veev valuat well tradit hcit name
line healthcar cloud enterpris softwar compani
concern market becom price
competit iqvia recent announc win
on-going litig iqvia medidata overhang
expans outsid tradit life scienc market provid
depend third parti
signific upsid compani explor heavili regul
featur impress growth profil beat revenu ep
estim last quarter
 reli salesforc com amazon web servic
contract exist relianc remain risk
expans core life scienc industri costli riski
win new custom outsid life
success launch onboard
client veev new plan offer
includ nitro andi publish vault
growth expans
demonstr success capit
in-sel opportun could gener
much addit revenu
short interest float
dental end-market remain healthi dental volum appear
robust anecdot medacorp kol report volum tend
follow slightli lag econom activ strong economi
volum therefor demand hsic offer like remain
may institut volume-bas price tailor toward
compani continu dso growth
signific opportun remain estim
market share north american dental anim health
market share medic
benefit abil sell full line dentspli
sirona lead cad/cam imag equip
equip sale though strong recent could risk dso
larg practic seek go direct manufactur
purchas servic
continu growth dental servic organ dso
featur concentr purchas power could erod margin
amazon continu grow dental busi could challeng
hsic domin posit provid margin pressur
addit on-line competitor like zensuppli could
pressur margin abl provid authent dental
materi attract price
y/i dental comp becom challeng
resolut on-going ftc complaint
could serv remov meaning
success growth vet first corp post
spin-off could gener meaning valu
acquisit captur market
expand reach
 anim health spin-off vet first
gener cash
use buyback
short interest float
valuat believ appropri methodolog valu share ev sale multipl current trade ev/sal
athn trade ev/sal respect next month expect evol share trade
ev/sal would put stock price target top-lin growth rate excel still fairli young compani turn
ebitda posit furthermor increment risk tie valenc health transact recent elect brought republican power
possibl repeal portion could caus delay hcit purchas decis among larg idn solid recur revenu model rapidli
grow address market estim popul health manag market somewhat new grow creat greater greenfield
opportun rel athn result rate share outperform
risk valuat relianc licens agreement upmc advisori board compani reli licens agreement upmc
advisori board compani upmc ip agreement upmc technolog agreement advisori board ip agreement addit
upmc ip agreement termin acquir certain entiti competitor upmc also licens use reproduc modifi access
busi plan oper model design creat advisori board compani compani oper could risk unabl maintain
agreement addit upmc licens agreement preclud conduct busi certain provid resel non-competit
agreement advisori board limit evh abil sell certain softwar technolog compet abco solut stand-alon basi
valenc transact pose risk acquir valenc health process migrat client upmc platform valenc
integr risk tie deal
data secur data privaci regulatori requir collect store analyz confidenti inform must maintain secur access data
patient clinic financi data must handl regulatori privaci requir mind may need take addit secur measur maintain
complianc rule regul unauthor access patient data could advers impact data loss corrupt on-line secur potenti
shift value-bas vbc capit guarante evh servic premis vision us continu see shift toward value-
base care reimburs model although sever challeng possibl transit could lose momentum earli vbc model limit
downsid risk make buy-in easier physician accept new payment model take time view
valuat current trade ep premium drug distribut pbm group esrx
next month expect share trade ep would put stock price
target valuat would slightli stock year histor averag ntm ep therefor reason view especi given
hsic consist abil grow market share deliv upsid expect acquisit believ current multipl alreadi reflect
improv sentiment risk/reward profil improv substanti
risk valuat competit relianc manufactur healthcar distribut industri north america intern highli
competit distributor compet basi price product offer custom servic valu ad product servic competitor obtain
exclus right manufactur distribut certain product manufactur bypass distributor altogeth could advers impact
earn larg competitor especi abroad use size increas price pressur group purchas organ gpo larg provid
may also demand lower price addit manufactur disrupt shortag result unabl meet custom demand certain
product seen flu vaccin shortag issu supplier relationship advers impact firm earn
acquisit restructur one largest player alternate-car market made numer acquisit domest
intern market acquisit joint ventur involv numer risk may integr well manag intend
success integr acquisit past immedi short-term impact bottom line drag earn year come
acquisit may result loss custom product line acquir busi may unintend effect area oper cost
increas relat restructur integr new busi advers impact firm earn margin
season quarterli fluctuat tradit sale higher third fourth quarter result end year custom purchas
pattern well flu season ill quarterli earn impact number factor includ sever flu season product
avail time price chang product releas vendor advers impact revenu firm
govern regul healthcar reform custom healthcar industri highli regul local state feder law
firm may need adapt procedur price result polici chang govern agenc pressur reduc budget deficit
balloon healthcar cost frequent target enact healthcar reform reduct reimburs rate public and/or privat insur
program could advers impact revenu profit margin foreign domest tax law also subject chang current interpret
subject scrutini challeng could advers impact firm earn
ftc litig su ftc alleg price collus believ like outcom complaint settlement
possibl complaint could expand grow crimin charg expand area busi
valuat initi coverag inc lead industri cloud platform life scienc consid biopharma
market leerink outperform rate price target veeva one profit cloud saa vendor thrive life scienc
industri veeva offer variou cloud base softwar solut compani look benefit central data collect manag analysi
veeva applic util like salesforc platform salesforc com amazon web servic span entir life cycl drug develop
initi clinic trial market sale allow streamlin process maxim valu custom number veeva product use
industri leader includ novarti merck compani addit veeva product suit provid emerg life
scienc compani opportun compet industri leader access capabl abil evolv chang technolog
custom market see life scienc industri expand cloud oper next year compani realiz valu add data
central potenti time save bring drug market one veeva recent launch platform qualityon provid avenu revenu
diversif begin expand busi target industri outsid life scienc includ chemic compani consum packag good
food beverag oil ga highli regul servic platform provid document control qualiti manag recent roll
custom encourag inc industri potenti whole move forward believ veeva posit
market leader increasingli competit grow environ result rate share outperform
risk valuat veeva rather high price multipl compar similar compani rel high multipl still pose threat valuat compani continu grow
around annual futur earn offer opportun bring multipl back sustain level time stock continu grow still see risk rel high price
multipl small swing may result oversel saw octob
life scienc compani begin switch infrastructur cloud veeva may experi increas competit legaci competitor industri focus
sap well industri focus competitor medidata iqvia competit custom yet make full switch cloud base
bargain power option legaci firm abl provid capit research develop toward industri well determin benefici long
veeva dedic time resourc toward provid cloud base client outsid life scienc industri qualityon product diversif plan may challeng cloud
base provid previous competitor veeva new competitor may industri specif platform veeva would compet diversifi away
life scienc industri may indic current custom focus grow product line industri long term
histor larg portion veeva revenu come small number custom fiscal year veeva top ten custom account total
revenu one custom account revenu although expand custom base improv revenu diversif within life scienc sector still
custom would pose threat revenu decid switch competitor null contract anoth reason
veeva multipl on-going litig matter claim file first iqvia formerli quintil im incorpor im softwar servic ltd collect iqvia file
complaint januari alleg unauthor access iqvia proprietari data improv veeva softwar data product way veeva design softwar steal trade
secret iqvia accus continu alleg unauthor access proprietari inform gain unfair advantag market veeva product multipl claim veeva made
fals
march veeva file counterclaim alleg iqvia abus monopoli power domin provid data product life scienc compani exclud veeva product respect
network claim accus iqvia engag tactic prevent custom switch veeva product increas difficulti cost switch platform involv compani still
wait court rule rule favor iqvia could result damag veeva brand oper stock price
also januari medidata file complaint veeva five individu employe previous work medidata complaint alleg veeva induc individu breach
employ agreement includ non-compet confidenti claus misappropri medidata confidenti trade secret inform complaint amend twice includ
voluntari dismiss individu without prejudic veeva motion compel arbitr deni argu appel court august veeva current await rule
 court appeal second circuit rule favor medidata may result damag veeva brand oper stock price
veeva experi secur breach regard sensit patient inform one platform risk neg press caus damag brand reput
veeva sale cycl span period year commerci cloud year veeva vault contract size variabl well depend number user custom
sign typic user base begin small grow length contract howev renew isnt guarante also possibl upon renew custom may expand suit
result lower expect retent revenu
mani veeva vault custom small earli stage pre-commerci compani expect compani may reach commerci howev present signific
earn potenti natur clinic trial like drug obtain fda approv small compani drug make process veeva risk lose
member custom base
veeva oper depend amazon web servic product includ veeva veeva vault respect well veeva commerci cloud applic
provid infrastructur data center part veeva multichannel applic also includ system administr configur report function
agreement expir septemb renew mutual agreement five-year period minimum order commit million must met term agreement
total million septemb full million contract expir septemb veeva equal exceed amount true payment requir
would neg impact earn potenti stock price upon expir agreement via one parti elect renew termin via breach
five-year wind period platform could still offer exist custom limit number new custom veeva breach contract
oper would sever risk host platform veeva migrat signific amount comput infrastructur need amazon web servic risk disrupt outag
downtim cost increas issu
custom depend veeva product produc relev accur inform time veeva must ensur full complianc strict adapt regul failur compli
regul includ audit trail track electron signatur captur data encrypt secur access control industri specif regul may result lawsuit neg press hinder
compani abil perform advers effect stock price
